Champions Oncology (FRA:2I3) EV-to-Revenue : 1.32 (As of Jun. 01, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Champions Oncology EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Champions Oncology's enterprise value is €59.88 Mil. Champions Oncology's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 was €45.27 Mil. Therefore, Champions Oncology's EV-to-Revenue for today is 1.32.

The historical rank and industry rank for Champions Oncology's EV-to-Revenue or its related term are showing as below:

FRA:2I3' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.84 Med: 2.96 Max: 12.95
Current: 1.31

During the past 13 years, the highest EV-to-Revenue of Champions Oncology was 12.95. The lowest was 0.84. And the median was 2.96.

FRA:2I3's EV-to-Revenue is ranked better than
85.22% of 1035 companies
in the Biotechnology industry
Industry Median: 8.1 vs FRA:2I3: 1.31

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-01), Champions Oncology's stock price is €4.10. Champions Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 was €3.34. Therefore, Champions Oncology's PS Ratio for today is 1.23.

Champions Oncology EV-to-Revenue Historical Data

The historical data trend for Champions Oncology's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology EV-to-Revenue Chart

Champions Oncology Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

EV-to-Revenue

Get a 7-Day Free Trial

3.78

2.92

3.63

2.12

1.21

Champions Oncology Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EV-to-Revenue	Get a 7-Day Free Trial															0.99	1.21	1.73	1.54	1.67

Competitive Comparison of Champions Oncology's EV-to-Revenue

For the Biotechnology subindustry, Champions Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Champions Oncology's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Champions Oncology's EV-to-Revenue falls into.

Champions Oncology EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Champions Oncology's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	59.877	/	45.269
	=	1.32

Champions Oncology's current Enterprise Value is €59.88 Mil.
Champions Oncology's Revenue for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €45.27 Mil.

Champions Oncology (FRA:2I3) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Champions Oncology's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	4.10	/	3.344
	=	1.23

Champions Oncology's share price for today is €4.10.
Champions Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.34.

Champions Oncology EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Champions Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Champions Oncology (FRA:2I3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (FRA:2I3) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CSBR:USA

Address

One University Plaza, Suite 307, Hackensack, NJ, USA, 07601

Website

https://www.championsoncology.com

Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.

Champions Oncology (FRA:2I3) Headlines

No Headlines